Sponsors

FDA approves Roche’s molecular blood test for malaria

Roche has announced the US Food and Drug Administration (FDA) approval of the cobas Malaria test for use on the cobas 6800/8800 Systems. This approved test can aid healthcare professionals in reducing potential risks of patient infection from transfused blood products. The cobas Malaria test provides a highly sensitive and specific solution to help ensure that infected blood units are removed from the blood supply.

The cobas Malaria molecular test screens whole blood samples for the five main species of Plasmodium parasites that are known to cause human infection. The potential value of a molecular donor screening test for malaria is to improve both blood safety and availability. The test is intended for use in screening blood, organ and tissue donors.

“As the first FDA-approved blood screening test for malaria, this represents an important step forward in safeguarding the global supply of donated blood," said Matt Sause, CEO of Roche Diagnostics. “The approval of cobas Malaria represents a significant advancement in malaria detection, offering healthcare professionals a reliable tool for donor screening and improving the safety of patients worldwide.”

Globally, a large number of possible donors are excluded from giving blood because of travel to or from residences in malaria-endemic areas. Existing microscopy and serological tests are not sensitive enough to reliably mitigate malaria transfusion risk.

The Roche Blood Safety Solutions offering provides the most comprehensive molecular, serological testing and automation options for donor screening in the US market.

The test will be available in the United States at the end of Q2 2024. Approval in CE-marked countries is anticipated later this year.

The cobas Malaria test is a qualitative in vitro nucleic acid screening test, which allows for direct detection of Plasmodium RNA and DNA in whole blood samples from individual human donors. The test, which can be performed with other routine blood donor screening tests, is designed for use on the cobas 6800/8800 Systems.

 

Latest Issues

ECP 2026 - 38th European Congress of Pathology

Stockholmsmässan, Stockholm, Sweden
12-16 September, 2026

UK NEQAS Parasitology Symposium

UKHSA, 61 Colindale Avenue, London NW9 5EQ
18 September, 2026

UKHSA Conference 2026

Manchester Central, Manchester, M2 3GX
22-23 September, 2026

Cardiac Marker Dialogues

Technology and Innovation Centre, University of Strathclyde, 99 George Street, Glasgow, G1 1RD
24-25 September, 2026

46th European Congress of Cytology

Hilton Antwerp Old Town, Antwerp
4-7 October, 2026